These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Antiplatelet agents for intermittent claudication. Wong PF; Chong LY; Mikhailidis DP; Robless P; Stansby G Cochrane Database Syst Rev; 2011 Nov; (11):CD001272. PubMed ID: 22071801 [TBL] [Abstract][Full Text] [Related]
6. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012169. PubMed ID: 28968483 [TBL] [Abstract][Full Text] [Related]
7. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Palmer SC; Di Micco L; Razavian M; Craig JC; Perkovic V; Pellegrini F; Copetti M; Graziano G; Tognoni G; Jardine M; Webster A; Nicolucci A; Zoungas S; Strippoli GF Ann Intern Med; 2012 Mar; 156(6):445-59. PubMed ID: 22431677 [TBL] [Abstract][Full Text] [Related]
8. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. Naqvi IA; Kamal AK; Rehman H Cochrane Database Syst Rev; 2020 Aug; 8(8):CD009716. PubMed ID: 32813275 [TBL] [Abstract][Full Text] [Related]
10. Antioxidants for chronic kidney disease. Jun M; Venkataraman V; Razavian M; Cooper B; Zoungas S; Ninomiya T; Webster AC; Perkovic V Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008176. PubMed ID: 23076940 [TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079 [TBL] [Abstract][Full Text] [Related]
12. Interventions for preventing thrombosis in solid organ transplant recipients. Surianarayanan V; Hoather TJ; Tingle SJ; Thompson ER; Hanley J; Wilson CH Cochrane Database Syst Rev; 2021 Mar; 3(3):CD011557. PubMed ID: 33720396 [TBL] [Abstract][Full Text] [Related]
13. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. De Schryver EL; Algra A; van Gijn J Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415 [TBL] [Abstract][Full Text] [Related]
16. Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138 [TBL] [Abstract][Full Text] [Related]
17. Interventions for weight loss in people with chronic kidney disease who are overweight or obese. Conley MM; McFarlane CM; Johnson DW; Kelly JT; Campbell KL; MacLaughlin HL Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013119. PubMed ID: 33782940 [TBL] [Abstract][Full Text] [Related]
18. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Squizzato A; Bellesini M; Takeda A; Middeldorp S; Donadini MP Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005158. PubMed ID: 29240976 [TBL] [Abstract][Full Text] [Related]
19. Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. Wang Y; Ivany JN; Perkovic V; Gallagher MP; Woodward M; Jardine MJ Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009631. PubMed ID: 27039404 [TBL] [Abstract][Full Text] [Related]
20. Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Su X; Yan B; Wang L; Lv J; Cheng H; Chen Y BMC Nephrol; 2019 Aug; 20(1):309. PubMed ID: 31390997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]